创新药巨头百济神州(BGNE.NS;06160.HK;688235.SH)再次成为市场关注焦点。据21世纪经济报道消息,百济神州大中华区首席商务官(CCO)殷敏被监管机构调查,一位不愿透露姓名的业内人士向该媒体证实了这一消息的真实性。截至发稿,殷敏本人未能取得联系,百济神州方面也未给出明确回应。从履历来看,殷敏于2022年1月正式加入百济神州,担任大中华区首席商务官。根据百济神州官网信息,她拥有...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.